Capital Investment Counsel Inc Has $386,000 Position in AbbVie Inc. $ABBV

Capital Investment Counsel Inc increased its holdings in AbbVie Inc. (NYSE:ABBV) by 97.2% in the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 2,079 shares of the company’s stock after purchasing an additional 1,025 shares during the period. Capital Investment Counsel Inc’s holdings in AbbVie were worth $386,000 at the end of the most recent quarter.

A number of other institutional investors also recently added to or reduced their stakes in ABBV. Brighton Jones LLC boosted its stake in shares of AbbVie by 17.4% in the 4th quarter. Brighton Jones LLC now owns 22,912 shares of the company’s stock valued at $4,072,000 after purchasing an additional 3,401 shares in the last quarter. Revolve Wealth Partners LLC lifted its holdings in AbbVie by 72.7% during the 4th quarter. Revolve Wealth Partners LLC now owns 7,279 shares of the company’s stock valued at $1,294,000 after purchasing an additional 3,064 shares during the last quarter. OVERSEA CHINESE BANKING Corp Ltd lifted its holdings in AbbVie by 5,956.4% during the 1st quarter. OVERSEA CHINESE BANKING Corp Ltd now owns 224,633 shares of the company’s stock valued at $47,000 after purchasing an additional 220,924 shares during the last quarter. PAX Financial Group LLC boosted its position in AbbVie by 27.7% in the first quarter. PAX Financial Group LLC now owns 2,731 shares of the company’s stock valued at $572,000 after buying an additional 592 shares in the last quarter. Finally, Bryn Mawr Capital Management LLC grew its stake in AbbVie by 10.2% during the first quarter. Bryn Mawr Capital Management LLC now owns 7,883 shares of the company’s stock worth $1,652,000 after buying an additional 729 shares during the last quarter. 70.23% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of research analysts have recently issued reports on the stock. JPMorgan Chase & Co. lifted their target price on shares of AbbVie from $250.00 to $260.00 and gave the company an “overweight” rating in a research note on Monday, November 3rd. Piper Sandler reiterated an “overweight” rating and issued a $289.00 price objective (up previously from $284.00) on shares of AbbVie in a research report on Wednesday, November 5th. Guggenheim increased their target price on AbbVie from $227.00 to $242.00 and gave the stock a “buy” rating in a report on Monday, October 20th. Citigroup lowered their target price on AbbVie from $240.00 to $235.00 and set a “neutral” rating for the company in a research note on Monday, November 3rd. Finally, Raymond James Financial set a $256.00 price target on shares of AbbVie in a research report on Monday, November 3rd. Two analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and ten have issued a Hold rating to the stock. According to data from MarketBeat.com, AbbVie currently has an average rating of “Moderate Buy” and an average price target of $236.57.

AbbVie Trading Up 3.7%

ABBV stock opened at $233.42 on Thursday. The company has a quick ratio of 0.61, a current ratio of 0.74 and a debt-to-equity ratio of 44.14. AbbVie Inc. has a twelve month low of $163.81 and a twelve month high of $244.81. The company has a market cap of $412.54 billion, a P/E ratio of 111.15, a PEG ratio of 1.42 and a beta of 0.50. The business has a fifty day moving average of $224.10 and a 200-day moving average of $203.43.

AbbVie (NYSE:ABBV) last announced its quarterly earnings data on Friday, October 31st. The company reported $1.86 EPS for the quarter, topping analysts’ consensus estimates of $1.77 by $0.09. AbbVie had a return on equity of 699.66% and a net margin of 6.45%.The firm had revenue of $15.78 billion during the quarter, compared to analyst estimates of $15.58 billion. During the same period last year, the company earned $3.00 earnings per share. The company’s revenue was up 9.1% on a year-over-year basis. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. As a group, equities research analysts expect that AbbVie Inc. will post 12.31 EPS for the current year.

AbbVie Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, February 17th. Shareholders of record on Friday, January 16th will be paid a $1.73 dividend. The ex-dividend date of this dividend is Friday, January 16th. This is a boost from AbbVie’s previous quarterly dividend of $1.64. This represents a $6.92 dividend on an annualized basis and a yield of 3.0%. AbbVie’s payout ratio is 524.24%.

AbbVie Profile

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.